Suzhou Abogen Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2019-01-10
- Employees
- 501
- Market Cap
- -
- Website
- http://www.abogenbio.com
Clinical Trials
4
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT06088004
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, China
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
Phase 2
Active, not recruiting
- Conditions
- COVID-19
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 14168
- Registration Number
- NCT05636319
- Locations
- 🇮🇩
RS Universitas Indonesia, Depok, Indonesia
🇮🇩RS YARSI, Jakarta, Indonesia
🇮🇩RSIJ Cempaka Putih, Jakarta, Indonesia
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05434585
- Locations
- 🇮🇩
Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
🇮🇩Persahabatan Hospital, Jakarta, Indonesia
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05433194
- Locations
- 🇦🇪
AL Kuwait Hospital, Dubai, United Arab Emirates
News
No news found